Michelina Cairo, MD, discusses the adverse effect profiles of trastuzumab emtansine and trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Michelina Cairo, MD
Advertisement
Articles by Michelina Cairo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
2
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
3
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5